Global Omega 3 Industry Until 2028



DUBLIN, December 1, 2021 / PRNewswire / – The Omega 3 Market Size, Share and Trend Analysis Report by Type (EPA, DHA), by Source (Marine, Plant), by Application (Supplements & Functional Foods, Infant Formula), By region (APAC, CSA) and segment forecast, 2020 – 2028 “ the report was added to ResearchAndMarkets.com offer.

The global omega 3 market size is expected to reach $ 3.82 billion by 2028, registering a CAGR of 7.8% over the forecast period. DHA and EPA may help improve brain health in children and heart health in adults, which is likely to drive market growth. The growing scope of omega 3s in pharmaceuticals also supports the consumption of the products. Gamers are focused on delivering high quality, pharmaceutical grade omega 3 fatty acids. For example, the Epax brand of FMC Corp. offers concentrated marine omega-3 fatty acids from sustainable and traceable raw materials and meets the requirements for high quality pharmaceutical ingredients. .

The global market is characterized by the presence of leading players, such as BASF SE, Koninklijke DSM NV, Lonza and Croda International Plc, which is expected to increase competition. Players focus on meeting specific customer needs in order to expand their customer base.

For example, Crius Life Sciences has the formulation ability to produce EPA / DHA with concentration level according to customer needs, such functionality provides a higher degree of freedom. Companies are using krill oil as an alternative source to fish oil due to the increasing levels of contamination in fish oil. For example, in november 2019, Aker BioMarine and Acasti Pharma have signed a krill oil supply agreement to develop an innovative drug against hypertriglyceridemia, using krill oil as a basic ingredient.

Highlights of the Omega 3 Market Report

  • Eicosapentaenoic Acid (EPA) held a 25.3% revenue share in 2020 and is expected to grow rapidly during the forecast period due to increasing demand from the pharmaceutical industry.
  • For example, BASF SE offers eicosapentaenoic acid ethyl ester Maxomega EPA 97 EE which can be used in Japanese drugs “Epadel” and American “Vascepa” for its cardiovascular health benefits.
  • Manufacturers are focusing more on developing new products to strengthen their presence in the market. For example, in november 2019, BASF launched Hepacor, which contains highly concentrated purified EPA and DHA, for the dietary management of non-alcoholic fatty liver disease (NAFLD)
  • The marine sources segment is expected to register the fastest CAGR of 8.1% during the forecast period due to increasing production of omega 3 from marine sources other than fish, such as krill oils and algae.
  • Seaweed oil is gaining popularity among vegan consumers because it does not contain traces of fish oil or fishy odor.
  • Companies Explore Alternative Sources to Marine Species Due to Rising Adoption of Herbal Products Globally
  • For example, in August 2019, Cargill received approval to produce omega 3 from canola, which can be widely used in the aquaculture feed industry
  • Infant Formula Segment Is Expected To Grow At The Fastest CAGR During The Forecast Period Due To Growing Infant Nutrition Awareness
  • The increasing consumption of breastmilk substitutes, which closely resemble the functionality and composition of breastmilk, is also expected to boost the infant formula segment.

Main topics covered:

Chapter 1. Methodology and scope

Chapter 2. Executive summary

Chapter 3. Omega 3 Market: Variables, Trends and Scope
3.1. Market lineage outlook
3.1.1. Parent Market Outlook
3.1.1.1. Functional ingredients
3.1.1.2. Nutraceuticals and functional foods
3.1.2. Related Market Outlook
3.1.2.1. Fish oil
3.1.2.2. Krill oil
3.2. Mapping of penetration and growth prospects
3.3. Value chain analysis
3.3.1. Commodity trends
3.3.1.1. Fish oil
3.3.2. Manufacturing trends
3.3.2.1. Technological trends
3.2.2.1.1. Omega 3
3.3.2.1.2. Krill oil
3.3.2.2. Trends in Outsourcing and Contract Manufacturing
3.3.3. Profit margin analysis
3.3.3.1. Average selling price analysis
3.3.3.2. Analysis of the average prices of Dha and Epa
3.3.4. Analysis of sales channels
3.3.5. Supplier selection criteria
3.4. Omega-3 analysis
3.4.1. New products
3.5. Technology overview
3.5.1. Technological trends
3.5.1.1. Omega 3
3.5.1.2. Krill oil
3.5.1.2.1. Multi-stage oil extraction
3.6. Regulatory framework
3.6.1. Product classification codes
3.6.2. Standards and conformities
3.6.3. Security
3.7. Market dynamics
3.7.1. Market Driver Analysis
3.7.1.1. Growing penetration of omega 3s in the active pharmaceutical ingredient market
3.7.1.2. Growing demand for food supplements
3.7.2. Analysis of market restrictions
3.7.2.1. Declining rate of growth of fish production
3.7.3. Industry challenges
3.7.3.1. Limited supply of alternative sources
3.8. Corporate environmental analysis
3.8.1. Industry Analysis: Porter’s
3.8.1.1. Bargaining power of suppliers
3.8.1.2. The bargaining power of buyers
3.8.1.3. Threat of substitution
3.8.1.4. The threat of new participants
3.8.1.5. Competitive Rivalry
3.8.2. PESTLE analysis
3.8.2.1. The political landscape
3.8.2.2. Environmental landscape
3.8.2.3. Social landscape
3.8.2.4. Technological landscape
3.8.2.5. Economic landscape
3.8.2.6. Legal landscape
3.8.3. Major transactions and strategic alliances
3.8.3.1. Joint ventures
3.8.3.2. Mergers and Acquisitions
3.8.3.3. Licenses & Partnership
3.8.3.4. Capacity expansion
3.8.3.5. Product development
3.8.3.6. Technological advance
3.9. Market entry strategies

Chapter 4. Omega 3 Market: Type Estimates and Trend Analysis
4.1. Market share and type movement analysis, 2020 and 2028
4.2. Docosahexaenoic acid (Dha)
4.2.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
4.3. Eicosapentaenoic acid (Epa)
4.3.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
4.4. Alpha-linolenic acid (Ala)
4.4.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)

Chapter 5. Omega-3 Market Source Estimates and Trend Analysis
5.1. Analysis of source movement and market share, 2020 and 2028
5.2. Marine source
5.2.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
5.3. Vegetable source
5.3.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)

Chapter 6. Omega 3 Market: Application Estimates and Trend Analysis
6.1. Analysis of application movement and market share, 2020 and 2028
6.2. Supplements and functional foods
6.2.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
6.3. Medications
6.3.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
6.4. Infant formulas
6.4.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
6.5. Animal feed and pet food
6.5.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)
6.6. Others
6.6.1. Market Estimates & Forecasts, 2017 – 2028 (Tons) (USD Million)

Chapter 7. Carrageenan Market: Regional Estimates and Trend Analysis

Chapter 8. Competitive landscape
8.1. Recent developments and impact analysis, by the main market players
8.1.1. Increased investments in capacity extensions (Impact – High)
8.1.2. Growing demand for omega 3 supplements (impact – high)
8.2. Company categorization
8.3. Positioning of the company in the market
8.4. Supplier landscape
8.4.1. List of major distributors, channel partners and end users
8.4.2. Competitive dashboard analysis, private / public
8.5. Public enterprises
8.5.1. Analysis of the company’s positioning on the market
8.5.2. Company Ranking
8.5.3. Market differentiators
8.5.4. WORK
8.6. Private companies
8.6.1. List of top emerging companies / technology disruptors / innovators
8.6.2. Geographic presence of the company

Chapter 9. Company Profiles
9.1. Aker Biomarine Antarctica As
9.1.1. Company presentation
9.1.2. Financial performance
9.1.3. Comparative analysis of products
9.1.4. Strategic initiatives
9.2. Health Orkla (Axellus).
9.2.1. Company presentation
9.2.2. Financial performance
9.2.3. Comparative analysis of products
9.2.4. Strategic initiatives
9.3. Basf Se
9.3.1. Company presentation
9.3.2. Financial performance
9.3.3. Comparative analysis of products
9.3.4. Strategic initiatives
9.4. Omega Protein Corporation.
9.4.1. Company presentation
9.4.2. Financial performance
9.4.3. Comparative analysis of products
9.4.4. Strategic initiatives
9.5. Gc Reiber oils
9.5.1. Company presentation
9.5.2. Financial performance
9.5.3. Comparative analysis of products
9.5.4. Strategic initiatives
9.6. Lonza
9.6.1. Company presentation
9.6.2. Financial performance
9.6.3. Comparative analysis of products
9.6.4. Strategic initiatives
9.7. Croda International plc
9.7.1. Company presentation
9.7.2. Financial performance
9.7.3. Comparative analysis of products
9.8. Epax
9.8.1. Company presentation
9.8.2. Financial performance
9.8.3. Comparative analysis of products
9.8.4. Strategic initiatives
9.9. Bioprocess Algae, LLC
9.9.1. Company presentation
9.9.2. Financial performance
9.9.3. Comparative analysis of products
9.10. Koninklijke Dsm NV
9.10.1. Company presentation
9.10.2. Financial performance
9.10.3. Comparative analysis of products
9.10.4. Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/ame4ht

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com



Comments are closed.